Harmony Biosciences (HRMY) Stock: Buy, Sell, or Hold?
HRMY - Harmony Biosciences Holdings, Inc. Common Stock
$41.52
0.42 (1.02%)
▲
5d:
-0.81%
30d:
+4.4%
90d:
+17.95%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When HRMY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: HRMY shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: HRMY shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$76.82
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$47.70
13.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HRMY is currently trading at $41.52, which is considered extended relative to its 30-day fair value range of $37.86 to $41.07. The stock's valuation (Forward PE: 6.2) is in line with its historical norms (5.9). At these levels, the market is pricing in 1.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HRMY is in a strong uptrend. Immediate support is located at $38.97, while resistance sits at $43.49.
Market Sentiment: HRMY scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $47.36 (+14.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HRMY is in a strong uptrend. Immediate support is located at $38.97, while resistance sits at $43.49.
Market Sentiment: HRMY scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $47.36 (+14.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$37.86 -
$41.07
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
27.1%
Protect Your Profits
Holding HRMY? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (26/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($47.36)
- NEUTRAL: Market pricing in 1.7% annual earnings growth - fairly valued
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$37.86 -
$41.07
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$38.97
Resistance Level
$43.49
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.21
Wall Street Target
$47.36
(+14.1%)
Revenue Growth (YoY)
30.3%
Earnings Growth (YoY)
88.2%
Profit Margin
18.9%
Valuation Premium vs History
+1.7% premium
PE vs Historical
6.2 vs 5.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.7%
(market-implied from PE analysis)
1-Year Target
$42.23
(+2%)
2-Year Target
$42.94
(+3%)
3-Year Target
$43.67
(+5%)
3-Yr Target (if PE normalizes)
(PE: 6→6)
PE COMPRESSION
$41.50
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 28.1%)
$283.16
(+582%)
Base:
(SPY PE: 6.2, Growth: 28.1%)
$87.18
(+110%)
Bear:
(PE: 5.3, Growth: 28.1%)
$74.10
(+79%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 13.48 | Current EPS (TTM): $3.05
Bull Case
$90.42
(+118%)
Analyst growth 100.0%, PE expands to 14.8
Base Case
$82.20
(+98%)
Market implied 100.0%, PE stable at 13.5
Bear Case
$27.95
(-33%)
Severe decline -20.0%, PE contracts to 11.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 4:28 AM ET
Data refreshes hourly during market hours. Next update: 5:28 AM
Data refreshes hourly during market hours. Next update: 5:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HRMY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
Advanced HRMY Option Strategies
Professional options setups generated by AI based on today's HRMY price and gamma walls.
